CytomX and Regeneron Expand Strategic Collaboration, Value Now Up to $4B
CytomX Therapeutics and Regeneron Pharmaceuticals have expanded their collaboration to develop conditional-activated bispecific cancer therapies. The partnership, which was initially worth $2B, has doubled in value to $4B. CytomX has received a payment of $37M for adding two new programs to the collaboration. The expanded partnership may reach a total potential value of up to $4 billion across six targets.
CytomX Therapeutics has announced the expansion of its strategic research collaboration with Regeneron Pharmaceuticals in the area of conditional bispecific therapeutics for cancer treatment . The partnership combines CytomX's PROBODY platform with Regeneron's Veloci-Bi platform, with a shared goal of developing novel therapies.
The deal, originally valued at approximately $2 billion, has been significantly expanded to include a $4 billion potential with up to $37 million in added upfront payments for two new programs . This move may boost investor confidence in Regeneron's pipeline, particularly in the oncology space. Analysts will be watching how this expanded partnership progresses in achieving the desired objectives and the timelines provided in this deal.
According to available information, CytomX will receive another payment of $37 million, taking the partnership's value up to $4 billion over six possible future targets .
Related Stocks
Powered by SentiSense - Intelligent Market Analysis